Drug Delivery

Nebulizer Testing

Measure aerosol output, particle size, emitted dose, and performance under simulated breathing conditions during nebulizer development.

APSD, aerosol output, formulation, breathing-profile, CFD, and stability studies matched to the nebulizer type, interface, and regulatory framework.

ISO 17025USP <601>USP <1601>ISO 27427Reviewed 2026-05-17
Request a quoteSubmit a sample

Testing nebulizers

Nebulizer testing shows how the liquid formulation, device technology, fill volume, interface, and breathing conditions affect measured aerosol output. USP <1601>, USP <601>, ISO 27427, and FDA inhalation guidance frame the in vitro endpoints commonly used for nebulized drug products. This testing can support prototype comparisons, formulation screening, device-drug compatibility assessments, and regulatory documentation when:

  1. APSD testing compares nebulized aerosols by MMAD, GSD, fine-particle dose, and stage mass under USP <601> and ISO 27427.
  2. Aerosol output and emitted-dose studies quantify delivery rate, total drug delivered, residual volume, and treatment completion under USP <1601>.
  3. Breathing simulation evaluates mouthpiece, mask, pediatric, adult, or circuit conditions using ISO 27427 profiles and FDA use-condition framing.
  4. Formulation screening links viscosity, concentration, suspension behavior, and assay recovery to aerosol performance under USP <1601> and ICH Q1A.
  5. Stability or aging pulls track PSD, emitted dose, residual volume, and assay drift under ICH Q1A or ASTM D4169 conditioning.

Use nebulizer testing when output rate, respirable fraction, interface loss, residual volume, or formulation drift could affect the delivered aerosol. Before samples arrive, a defined protocol establishes the device state, fill volume, flow, breathing profile, collection method, assay, and acceptance logic.

Core test menu for nebulizer programs

Nebulizer programs often combine aerosol sizing, emitted-dose, breathing-profile, formulation, modeling, and stability studies. The appropriate test set depends on the device technology, formulation state, interface, and submission need.

Test method options

MethodStrengthsTradeoffAligned with
Nebulizer APSD and aerosol output package
  • Cascade impactor plus output collection quantifies MMAD, GSD, fine-particle dose, delivery rate, and residual volume under USP <1601>.
  • ISO 27427 setup logic supports jet, mesh, and ultrasonic nebulizer comparisons with declared flow, fill, and treatment conditions.
Higher setup and assay burden than screening; best after device configuration, formulation, and interface are selected.
USP <1601>ISO 27427
Emitted dose and residual volume series
  • Dose capture quantifies total emitted dose, output rate, treatment completion, and residual dose under USP <1601>.
  • HPLC or ELISA recovery controls connect collection mass to active-specific output for FDA inhalation documentation.
Collection fixtures must fit the nebulizer cup, outlet, mouthpiece, mask, or circuit before dose comparisons are meaningful.
USP <1601>FDA MDI / DPI / nasal
Breathing-profile and interface evaluation
  • Programmable profiles test delivered dose through mouthpiece, mask, chamber, or circuit conditions with ISO 27427 context.
  • Adult and pediatric profile sweeps separate device output from interface loss, inhalation timing, and treatment-duration effects.
Results depend on profile assumptions and fixture leakage, so use-condition rationale must be declared before testing.
ISO 27427FDA MDI / DPI / nasal
Formulation and stability-linked screening
  • Viscosity, concentration, suspension behavior, and assay recovery can be screened against aerosol output under USP <1601>.
  • Storage pulls track PSD, emitted dose, residual volume, and assay drift across ICH Q1A timepoints.
Study duration follows storage and pull timing; formulation design and acceptance criteria remain sponsor-owned.
USP <1601>ICH Q1A
CFD-supported fixture and deposition study
  • Modeling estimates airflow, aerosol transport, interface losses, and sampling geometry using FDA engineering rationale.
  • Bench PSD, dose, or breathing-profile data provide validation points so model outputs stay tied to measured behavior.
CFD supports interpretation and fixture design; it does not replace compendial aerosol output or APSD measurement.
FDA MDI / DPI / nasal

Setup configurations

Each nebulizer study is configured around the device technology, formulation, interface, and endpoint. Jet, mesh, and ultrasonic systems may respond differently to changes in fill volume, drive gas, power setting, treatment time, and breathing profile. Before testing begins, the study plan defines the device state, collection geometry, assay recovery plan, environmental controls, and replicate structure.

Device interfaces

Mouthpieces, masks, chambers, tubing, circuit adapters, and collection fixtures matched to the nebulizer outlet and intended use condition.

Flow & actuation profiles

Drive gas, power setting, treatment duration, breathing waveform, inhalation flow, sampling flow, and start-stop timing documented for each run.

Sample numbers

Device count, fill count, replicate count, and treatment repeats sized to variability, assay sensitivity, and screening versus documentation need.

Media & handling

Fill volume, formulation state, dilution, collection solvent, extraction procedure, residual-volume handling, and storage conditions set before testing.

Environmental controls

Temperature, RH, storage condition, aging state, and cleaning state logged when formulation or device output may shift with conditioning.

Quality frame for nebulizer testing

Nebulizer studies are conducted within a documented quality system based on the compendial and consensus references used for inhalation products, nebulizing systems, and traceable aerosol measurement.

  • ISO 17025AccreditedLaboratory competence, calibration traceability, method control, and uncertainty contributors.
  • USP <601>AccreditedInhalation aerosols and sprays, including APSD and delivered-dose performance tests.
  • USP <1601>AlignedProducts for nebulization and characterization of nebulized drug output.
  • ISO 27427AlignedNebulizing systems, components, aerosol output, and particle size expectations.

Key data outputs & reporting

Nebulizer programs receive endpoint-specific datasets that link the device setup to measured aerosol performance. Deliverables may include APSD tables, output-rate and emitted-dose statistics, residual-volume records, breathing-profile dose data, assay recovery, and QA/QC controls. Reports are structured for development review, method justification, comparability packages, or interpretation of stability trends. Extended deliverables can include appendices covering interface comparisons, model validation, or storage pulls.

Primary outputs

  • APSD stage mass, MMAD, GSD, fine-particle dose or fraction, impactor recovery, and active-specific assay results where applicable.
  • Aerosol output rate, total emitted dose, residual volume, treatment duration, and dose statistics by device, fill, and condition.
  • Breathing-profile or interface data, including delivered dose by mouthpiece, mask, chamber, or circuit setup.
  • Formulation or stability outputs, including assay recovery, PSD drift, emitted-dose drift, and residual-volume trends.

Deliverables

#FormatContents
01PDF reportProtocol summary, setup, controls, deviations, results, and interpretation limits.
02CSV / XLSX datasetsStage mass, output-rate, emitted-dose, residual-volume, and assay tables.
03FiguresPSD curves, output profiles, dose summaries, and comparison plots.
Extended deliverables · multi-arm comparability · stability · predicate studies
  • Interface comparison appendix — Side-by-side mouthpiece, mask, chamber, or circuit results with declared profile and fixture assumptions.
  • Stability trend pack — Timepoint tables and figures showing PSD, emitted dose, residual volume, assay, and device-output drift.
  • Model validation notes — CFD assumptions, boundary conditions, and measured data used to ground airflow or deposition outputs.

QA / QC & data integrity

Each nebulizer study includes a QA/QC plan matched to the selected endpoints, assay, and regulatory framework. Controls are run alongside sample collection so particle size, output, dose, and formulation data remain traceable from sample receipt through the final report. Method deviations, invalid runs, and sources of uncertainty are documented rather than obscured in summary tables.

Blanks, background checks, comparator devices, or reference runs defined by endpoint and collection train.

Flow meters, balances, impactor stages, sizing instruments, timers, and breathing simulators checked or calibrated before use.

Assay controls for HPLC, ELISA, qPCR, or ddPCR, including calibration standards and recovery checks when required.

Chain of custody for devices, fills, collected stages, filters, extracts, raw files, and analyst observations.

Predefined acceptance criteria, replicate rules, deviation handling, environmental logs, and outlier logic included in the protocol.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
QualityDocumented study records
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

Quick answers to questions nebulizer development and regulatory teams ask when scoping a study: which endpoints to combine, how device and fill variables are controlled, what breathing profiles change, and what documentation is delivered. Most nebulizer programs need at least one custom fixture, interface, or assay decision that is best resolved during study planning together.

Q.Which nebulizer particle-size method should I choose?
A.Use cascade impactors when the study requires APSD, MMAD, GSD, and fine-particle dose. APS or laser diffraction can provide faster screening, with key decisions confirmed using the regulator-aligned method.
Q.Can ARE Labs measure aerosol output and residual volume?
A.Yes. When the assay is defined, nebulizer studies can quantify output rate, total emitted dose, treatment duration, residual volume, and active-specific recovery.
Q.Can you test mouthpiece, mask, or circuit setups?
A.Yes. We configure fixtures for mouthpieces, masks, chambers, tubing, or circuits using defined breathing profiles, sampling flows, and collection endpoints.
Q.How many devices or fills are needed?
A.The required device count, fill count, replicate count, and treatment repeats depend on expected variability, assay sensitivity, the selected endpoint, and whether the study is intended for screening or documentation support.
Q.Does this replace full device certification?
A.No. ARE Labs provides aerosol performance data, method development, and regulatory documentation for defined scopes. Electrical safety, software validation, clinical testing, labeling, and submission management may still be required.

Standards & guidance

ARE Labs aligns nebulizer test programs with the compendial, consensus, and regulatory references that govern nebulized aerosol characterization. Work within an accredited scope is identified as accredited; other references are described as aligned or conformant where applicable. The rows below summarize the standards and guidance clusters most often cited for nebulizer APSD, aerosol output, emitted dose, breathing-profile testing, CFD rationale, and stability support.

Inhalation & Drug Delivery - Accredited

USP <601>

Inhalation aerosols and sprays: APSD, delivered dose, and performance quality testsView standard ->Inhalation & Drug Delivery - Aligned

USP <1601>

Products for nebulization, aerosol output, total drug delivered, and aerodynamic assessmentView standard ->Inhalation & Drug Delivery - Aligned

ISO 27427

General-purpose nebulizing systems, aerosol output, and particle size characterizationView standard ->QA & Regulatory - Aligned

FDA MDI / DPI / nasal

Quality considerations for inhalation products, comparability, device changes, and CMC supportView standard ->QA & Regulatory - Aligned

ICH Q1A

Stability storage conditions, pull timing, and trend interpretation for drug productsView standard ->Packaging & Stability - Aligned

ASTM D4169

Distribution-cycle conditioning before post-stress aerosol performance evaluationView standard ->

Related testing services

Test

Particle Size Distribution (PSD) Testing

Pairs with nebulizer output studies to quantify APSD, MMAD, GSD, and fine-particle dose under controlled collection.Read more ->Test

Dose Uniformity & Emitted Dose

Core nebulizer output test for total emitted dose, delivery rate, residual volume, and treatment-completion behavior.Read more ->Test

Breathing Simulation Testing

Adds adult, pediatric, mouthpiece, mask, chamber, or circuit profiles to evaluate use-condition delivered dose.Read more ->Test

Pharma Formulation Support

Connects viscosity, concentration, suspension behavior, and assay recovery to nebulizer aerosol output and PSD.Read more ->Test

Computational Fluid Dynamics (CFD)

Supports airflow, interface loss, deposition interpretation, and fixture design when nebulizer geometry affects performance.Read more ->Test

Stability & Accelerated Aging

Pairs storage pulls and conditioning with nebulizer PSD, emitted dose, residual volume, assay, and output-rate trending.Read more ->